BioSyent Declares First Quarter 2023 Dividend
01 févr. 2023 16h30 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, Feb. 01, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly...
BioSyent Signs Exclusive Agreement for Oncology Supportive Care Product
14 déc. 2022 16h50 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, Dec. 14, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has signed an...
BioSyent Announces Renewal of Normal Course Issuer Bid
13 déc. 2022 08h00 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, Dec. 13, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX Venture Exchange (“TSX-V”) has accepted the...
BioSyent Releases Q3 and YTD 2022 Financial Results
16 nov. 2022 19h07 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, Nov. 16, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and nine months ended September 30, 2022. Key...
BioSyent Schedules Q3 and YTD 2022 Earnings Release for November 16, 2022
10 nov. 2022 09h00 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, Nov. 10, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and nine months ended...
BioSyent Initiates First Dividend
12 oct. 2022 17h45 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, Oct. 12, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly...
BioSyent to Present at the Virtual MicroCap Leadership Summit
14 sept. 2022 16h30 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, Sept. 14, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that it has been selected to present at the 7th annual...
BioSyent Announces Adoption of Dividend Policy
23 août 2022 16h55 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, Aug. 23, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors (the “Board”) today adopted a...
BioSyent Releases Q2 and H1 2022 Financial Results
23 août 2022 16h45 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, Aug. 23, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and six months ended June 30, 2022. Key...
BioSyent Schedules Q2 and H1 2022 Earnings Release for August 23, 2022
16 août 2022 19h14 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, Aug. 16, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and six months ended June 30,...